Overview

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Status:
Not yet recruiting

Trial end date:
2026-08-17

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab